

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**214410Orig2s000**

**OFFICER/EMPLOYEE LIST**

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** August 12, 2022

**TO:** Administrative file for NDA 214410/Original 2

**FROM:** Christine Kim, PharmD, RAC-US, Senior Regulatory Project Manager  
Antivirals Group, Division of Regulatory Operations for Infectious Diseases  
Office of Regulatory Operations

**SUBJECT:** Officer/Employee List for NDA 214410/Original 2

**APPLICATION/DRUG:** NDA 214410/orig 2, Xofluza (baloxavir marboxil), 2% granules,  
for oral suspension (2 mg/mL)

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Baylor, Melisse  
Birnkrant, Debra  
Bradley, Katharine  
Bunner, Anne  
Chikhale, Elsbeth  
Diggs, Deacqunita  
Earp, Justin  
Fanari, Melina  
Fuller, Barbara  
Ghantous, Hanan  
Grimstein, Christian  
Guerrieri, Peter  
Ince, William  
John, Mathew  
Kapoor, Rachna  
Kim, Christine  
Kolejian, Sevan  
Koolivand, Abdollah  
Kraft, Jeffrey  
Kronstein, Philip  
Liu, Jinzhong  
Mayrosh, Ruth  
Min, Stacey

O'Rear, Julian  
Sampson, Mario  
Sellers, Jenn  
Singer, Mary  
Smith, Fraser  
Valappil, Thamban  
Vaughan, Valerie  
Wang, Hailin  
Wang, Yifan (Katie)  
Winestock, Karen  
Wu, Kunyi  
Zhao, Yang  
Zuck, Karina

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

CHRISTINE KIM  
08/12/2022 08:58:26 AM